By the 1950s, kidney disease was clearly recognized as a common complication of diabetes, with as many as 50% of patients with diabetes of more than 20 years having this complication. Currently, diabetic nephropathy is the leading cause of chronic kidney disease in the United States and other Western societies. It is also one of the most significant long-term complications in terms of morbidity and mortality for individual patients with diabetes. Diabetes is responsible for 30-40% of all end-stage renal disease (ESRD) cases in the United States. Generally, diabetic nephropathy is considered after a routine urinalysis and screening for micro-albuminuria in the setting of diabetes. Patients may have physical findings associated with long-standing diabetes mellitus. Good evidence suggests that early treatment delays or prevents the onset of diabetic nephropathy or diabetic kidney disease. Regular outpatient follow-up is key role in managing diabetic nephropathy successfully. Type II diabetes is a significant health concern in the United States and its prevalence is expected to triple by 2050. Both metformin and exercise have shown to be effective in the management of blood glucose control. Both metformin and exercise have a positive and significant role in the management of type 2 diabetes and appear to work similarly to help manage blood glucose control. Recent clinical trials like Magnetic Molecular Energizer (MME), Bi-Axial Rotating Magnetic Field Therapy are some of the treatment which under trials. This will be lead to great discovery in this field. This can be useful step towards treating a major complication of diabetic and to save diabetic people from severe disease.
Keywords: Magnetic Molecular Energizer (MME), Bi-Axial Rotating Magnetic Field Therapy, Diabetic Neuropathy, micro-albuminuria.
- Tripathi K.D, Essential of Pharmacology, 2003,271.
- Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harb Perspect Med. 2012,3: 457-461.
- Richard. A. Harvey; Pamelac Champe, Pharmacology, 2005, 375.
- SatoshkarR.A, BhandarkarS.D, Pharmacology & Pharmacotherapeutics, 2004, 874.
- Yip JW, Jones SL, Wiseman MJ, Hill C, Viberti G. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. Diabetes. 1996
- David. A. wiliams; Thomas. L. lemke; Foye’s principle of medicinal chemistry, 2005,635.
- Vallance P, Smart TG (January 2006). The future of pharmacology. British Journal of Pharmacology.
- James Smith; Viktor Stein (2009). SPORCalc: A development of a database analysis that provides putative metabolic enzyme reactions for ligand-based drug design. Computational Biology and Chemistry 33 (2): 149–159.
- Rahman, SZ; Khan, RA (Dec 2006). Environmental pharmacology: A new discipline. Indian J Pharmacol. 38 (4): 229–30.
- Brater DC, Daly WJ (May 2000). Clinical pharmacology in the middle Ages: principles that presage the 21st century. Clin. Pharmacol. Ther. 67 (5): 447–50.
- Pratley, RE; Rosenstock, J; Pi-Sunyer, FX; Banerji, MA; Schweizer, A; Couturier, A; Dejager, S (December 2007). Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 30 (12): 3017–22.
- Budhiraja R.D., Elementry Pharmacology And Toxicology, Fourteehth Edition revised; Publication Year :2011
- Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care. 2013 Nov.
- Hall JE, Henegar JR, Dwyer TM, Liu J, Da Silva AA, Kuo JJ. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther. 2004 Jan.